Navigation Links
OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Date:6/17/2010

could total up to $387.5 million per program, including potential net sales milestones upon successful commercialization of biotherapeutic products.  In addition, OncoMed will be eligible to receive double-digit royalties on net product sales.  The agreement contains provisions under which OncoMed may co-develop antibody and protein therapeutics with Bayer.  The collaboration includes OncoMed's lead Wnt pathway antibody, OMP-18R5, which is currently planned to enter clinical testing in 2011.

In addition, Bayer will lead the discovery and advancement of small molecule therapeutic candidates that modulate Wnt pathway signaling.  OncoMed will assist Bayer in the evaluation and advancement of small molecule candidates, and is eligible to receive milestone payments of up to $112 million per candidate upon successful development and regulatory approval, including potential net sales milestones upon successful commercialization of small molecule products. In addition, OncoMed will be eligible to receive single-digit royalties on net product sales.

"At Bayer, we recognize the high unmet medical need for cancer treatments. This collaboration with OncoMed demonstrates our commitment to the development of new and innovative treatment options," said Prof. Andreas Busch, Head of Global Drug Discovery and Member of the Board of Management at Bayer Schering Pharma. "The development of anti-cancer stem cell therapeutics together with OncoMed is a highly innovative approach with the potential to perfectly complement our oncology portfolio. Anti-cancer stem cell research could turn out as one of the missing pieces in today's cancer therapy."  

"Our alliance with Bayer represents a major opportunity to discover and develop an entirely new class of anti-cancer stem cell therap
'/>"/>

SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
3. OncoMed Pharmaceuticals Completes Series B Financing
4. Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
5. Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
6. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
7. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
10. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 Pipette.com announces their ... Twitter followers can submit their #HolidayInTheLab pictures for a ... lab mates. , For those struggling to think of ... Pipette.com Holiday in the Lab Contest provides the ideal ... followers to send pictures of their chemistree, holiday ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  NeuroLifeSciences ... of mazindol in children with attention deficit/hyperactivity disorder published ... 2014 . The paper, titled "Pilot ... deficit/hyperactivity disorder" ( Konofal et al, Drug ... 2014 ) shows that mazindol might be an ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... BioTechnologies, Inc. (TriLink) and Lucigen Corporation (Lucigen) announced today ... for the use of TriLink,s CleanAmp™ dNTPs in Lucigen,s ... CleanAmp™ dNTPs are an innovative approach to Hot Start ... PCR assay with CleanAmp™ dNTPs, a Hot Start reaction ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY ), ... to June 30, 2011. Financial Highlights Q2 2011(1) ... GAAP operating income $342 million +26% US GAAP operating income $283 ... GAAP diluted earnings per ADS $1.08 +26% Non GAAP cash generation ...
... Pharmaceuticals, Inc. (NASDAQ: CADX ), a biopharmaceutical company ... use in the hospital setting, today announced that it will ... on Wednesday, August 3, 2011. Cadence management ... the financial results on Wednesday, August 3, 2011 at 1:30 ...
Cached Biology Technology:TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation 2Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 2Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 3Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 4Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 5Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 6Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 7Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 8Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 9Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 10Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 11Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 12Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 13Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 14Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 15Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 16Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 17Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 18Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 19Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 20Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 21Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 22Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 23Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 24Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 25Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 26Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 27Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 28Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 29Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 30Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time 31
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... believe decision making mechanisms in the human brain could mirror ... similarities have been found in decision making systems between humans ... bees could teach us about how our brains work. ... an often paralysing thought process in humans, with scouts who ...
... Queen,s University infectious disease expert has collaborated in the development ... rooms all over the world are cleaned as well as ... "This is the future, because many hospital deaths are preventable ... Quinte Health Care,s new Chief of Staff. "It has been ...
... scores of applications to develop utility-scale solar power installations ... too little is known to judge their likely effects ... December 2011 issue of BioScience . Although solar ... available information suggests a worrisome range of possible impacts. ...
Cached Biology News:Swarms of bees could unlock secrets to human brains 2New disinfection technique could revolutionize hospital room cleaning 2Solar power development in US Southwest could threaten wildlife 2
... is the cycler that revolutionized thermal ... and swappable blocks ensure consistent results, ... rugged machine is more than just ... new features and upgrades as research ...
Request Info...
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Soybean-Casein Digest Medium (TSB), USP is a ... for general laboratory use. Due to the ... the medium will support growth of many ... etc. , Product conforms to United States ...
Biology Products: